SSG
PLRX icon

Summit Securities Group’s Pliant Therapeutics PLRX Stock Holding History

Summit Securities Group’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,992
Closed -$2.31K – 1286
2025
Q2 		$2.31K Buy
1,992
+1,859
+1,398% +$2.63K ﹤0.01% 1015
2025
Q1 		$180 Buy
+133
New +$807 ﹤0.01% 737
2024
Q3 		– Sell
-5,532
Closed -$59K – 797
2024
Q2 		$59K Buy
+5,532
New +$71.3K 0.01% 265

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Summit Securities Group's PLRX Position: Q3 2025 in Review

Summit Securities Group sold out of Pliant Therapeutics (PLRX) in Q3 2025, closing a stake of 1,992 shares — an estimated $2.31K sold.

Summit Securities Group first reported a position in PLRX in Q2 2024 and held it in 3 quarters. The position peaked at $59K in Q2 2024. 99 funds tracked by Wall St. Rank hold PLRX as of Q3 2025.

  • Summit Securities Group reported no remaining Pliant Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Summit Securities Group sold 1,992 Pliant Therapeutics shares in Q3 2025, an estimated $2.31K.
  • Summit Securities Group first reported a position in Pliant Therapeutics in Q2 2024 and held it in 3 quarters.
  • Summit Securities Group's Pliant Therapeutics position peaked at $59K in Q2 2024.
  • 99 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2025.

Based on Summit Securities Group's 13F filing for Q3 2025, filed 13 Nov 2025.